Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007

Abstract

A marked improvement has occurred in the survival of patients with cystic fibrosis with an FEV(1) less than 30% predicted. Secondary analyses suggest that some of this improvement may be due to use of recombinant human DNase.